Menu

Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


Print

UMass gets 5-year, $11 million research grant for Alpha-1 gene therapy

Thursday, August 11, 2016
The National Heart, Lung, and Blood Institute (NHLBI) has awarded an $11 million, five-year grant to the University of Massachusetts Medical School to study new approaches to Alpha-1 gene therapy. Members of the UMass program project grant...
Divider

Alpha-1 Foundation leaders go to The White House to advocate better forms of detection and treatment for Alphas

Thursday, July 14, 2016
WASHINGTON – Alpha-1 Foundation representatives traveled to The White House this week to advocate better forms of detection and treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1) under President Barack Obama’s Precision Medicine...
Divider

New targeted gene therapy could lead to improved treatments for Alphas

Monday, July 11, 2016
Researchers at Boston University are examining whether delivering gene therapy directly to the lungs of mice could improve treatment for Alphas. Andrew Wilson, MD Current therapies add normal alpha-1 antitrypsin (AAT) protein into the...
Divider

Researchers show off “gene editing” technique to Alpha-1 support group

Friday, June 3, 2016
Researchers are looking for a way to genetically “edit” out Alpha-1 in much the same way that a writer corrects misspelled words, or a film editor cuts old frames and splices in new ones. Members of the Alpha-1 Mainers Support Group...
Divider

Pope calls for "empathy" in treating people with rare diseases

Tuesday, May 3, 2016
Pope Francis told participants in a Vatican health summit on Friday that a renewed sense of empathy should fuel their work and research, particularly regarding treatment for people who have rare diseases. Pope Francis “It is fundamentally...
Divider

The Alpha-1 Project extends funding for NIH-NCATS fellowship for a third year

Wednesday, April 13, 2016
The Alpha-1 Project has announced that it will extend funding for the postdoctoral fellowship at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) for a third year. The extension follows...
Divider

Alpha-1-To-One magazine Spring issue in your mail now

Wednesday, March 30, 2016
The Spring 2016 issue of Alpha-1-To-One magazine has been mailed to well over 20,000 people with free subscriptions, and will soon be available online. This is the cover story, "In search of new therapies for Alpha-1,"  part of a...
Divider

Kamada applies to market inhaled Alpha-1 therapy in Europe

Tuesday, March 29, 2016
Kamada has submitted a Marketing Authorization Application with the European Medicines Agency (EMA), seeking permission to market its inhaled therapy for Alpha-1 Antitrypsin Deficiency in Europe. The EMA, the European equivalent of the U.S. Food...
Divider

Conference to address ethical issues in rare disease research

Wednesday, March 23, 2016
People with rare diseases such as Alpha-1 deserve treatments that are proven to be safe and effective. Christine Grady, PhD But unlike more common diseases, rare diseases offer fewer patients who are able to participate in clinical trials to...
Divider

Celtic Connection raises more than $115,000 for Alpha-1 Foundation

Thursday, March 17, 2016
The corn beef and cabbage, carrots and potatoes were boiled to order. The award-winning Irish step dancers and a live Irish band complemented the Celtic cuisine to create a festive mood, all while helping to raise money for the fight against...
Divider

Alpha-1 Foundation congratulates Califf on confirmation as new FDA commissioner

Thursday, February 25, 2016
The Alpha-1 Foundation today congratulated Robert Califf, MD, on his confirmation as the new commissioner of the U.S. Food and Drug Administration (FDA). Ab Rees, Alpha-1 Foundation acting CEO and president The U.S.  Senate confirmed...
Divider

UK researchers claim Alpha-1 developed to combat Viking worm infestations

Monday, February 8, 2016
In the complex world of DNA, a gene that develops to protect a population from one health problem, may later put that same population at risk for a very different problem. According to researchers in England, this is true of Alpha-1 Antitrypsin...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.